Yikai Wang
王一恺
Yikai Wang is a biotech founder and former investor who moved from industry to venture capital and back again. He holds degrees from Peking University and Harvard, and spent time at WuXi AppTec's domestic new drug R&D services division before joining FreeS Fund (峰瑞资本) in March 2018 as a biotech investor . At FreeS he sourced deals including an angel investment in Chemical.AI (智化科技) in March 2019, where he met founder Xia Ning and decided to back the AI-driven chemistry platform within half an hour . In September 2020 he founded Keen Therapeutics (科因生物), a biotech company positioned to leverage new tool platforms and efficiency technologies for globally competitive drug development . As he described it in a 2021 FreeS Fund interview, his path—industry to investment and back to industry—gave him unusual exposure to the full R&D chain at a relatively young age .
AI-generated — may contain errors, please verify.
Coverage
The 6 Questions Young People Care About Most: We Asked 17 Founders | FreeS Fund Youth Festival & Graduation Season Special
Passion and conviction are what carry you through the darkness.
Farewell to a Year of Inflection Points: Will 2022 Be Better? | Li Feng's New Year Outlook
Where the heart leads, steady steps take you far.
"There Will Come a Moment When Technology Defeats Human Experience" | A Conversation with FreeS Fund
"There will come a moment when technology surpasses human experience."
FreeS Fund Earns Ten Honors from Zero2IPO, PEDaily, ChinaVenture & GEW, CVCRI, ChinaRong360, Wanbang RB, and Lancha Consumer | FreeS Matters
Continuously hiring investors
Live at 10 AM Tomorrow | New Opportunities in the Changing Landscape of Drug R&D
See you tomorrow at 10 a.m. sharp.
How Should We Think About the Present and Future of Drug R&D? | FreeS Fund Dialogue Vol. 2 — Final 2 Days to Register
What new variables and opportunities are emerging in the drug development industry?
FreeS Fund Report 25: Food Investment Through the Lens of China's Dietary Structure
What will we eat in the future?
New Opportunities Amid the Great Transformation in Drug R&D | FreeS Fund Dialogue Session 2 Now Open for Registration
Breakthroughs and Acceleration in New Drug R&D
Biotech Firms Raise Nearly 4 Billion Yuan, Consumer Companies Land Over 1.4 Billion | FreeS Family Funding Roundup · August
We've also released three short videos this week — follow us to check them out.
FreeS Report 23: Crossing the "Valley of Death": Systemic New Opportunities in Small-Molecule Drug R&D
Across every stage of preclinical drug R&D, new infrastructure, methods, and tools are emerging in China — making rapid, low-cost experimentation possible.
Riding the Gene Therapy Wave | Frees Fund
From Willow Bark to "God's Scalpel" — A Brief History of Drug Development
The Hammer and the Dance: Where Healthcare Investment Goes Next Under COVID-19 | FreeS Fund
The unexpected arrival of COVID-19 turned out to be a shot in the arm for the healthcare industry.
Investment Opportunities in the Pharmaceutical and Chemical Industry Upgrade | Frees Fund
Technology Transfer and Innovation-Driven Growth
FreeS Fund Report 15: The Life Gamble — The Risk-Filled Journey of Drug R&D | Frees Fund
The Ideals and Persistence Behind a 3% Success Rate.
